Pacira BioSciences, Inc. (PCRX)
Market Cap | 1.52B |
Revenue (ttm) | 669.23M |
Net Income (ttm) | -4.57M |
Shares Out | 49.65M |
EPS (ttm) | -0.16 |
PE Ratio | n/a |
Forward PE | 8.57 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 738,365 |
Open | 31.12 |
Previous Close | 30.85 |
Day's Range | 30.43 - 31.12 |
52-Week Range | 30.43 - 58.10 |
Beta | 0.70 |
Analysts | Strong Buy |
Price Target | 57.33 (+86.86%) |
Earnings Date | Nov 2, 2023 |
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsula... [Read more]
Full Company ProfileFinancial Performance
In 2022, PCRX's revenue was $666.82 million, an increase of 23.14% compared to the previous year's $541.53 million. Earnings were $15.91 million, a decrease of -62.10%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $57.33, which is an increase of 86.86% from the latest price.
News

Pacira BioSciences Announces Leadership Succession Plan
David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), ...

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Inve...

Pacira BioSciences Reports Second Quarter 2023 Financial Results
-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management ...

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global He...

Pacira BioSciences Reports First Quarter 2023 Financial Results
-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET --

Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on We...

Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an...

Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22nd Annual Needham Virtual Heal...

Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court's dism...

Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an...

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confe...

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
— Record revenues of $667 million in 2022 —

Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before t...

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December EXPAREL average daily sales 104% of the prior year for the fourth quarter...

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM E...

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its c...

Pacira BioSciences to Present at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferen...

Pacira BioSciences Reports Third Quarter 2022 Financial Results
-- Third quarter revenue of $167 million , increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq:...

Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu...

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Compa...

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older
-- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2022 -- -- European Commission decision on the Marketing Authorization Application (MAA) expected ...

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 –

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours Study achieved primary and key secondary endpoin...

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitm...

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain
-- Multi-year initiative will leverage NFL Alumni events and educational opportunities to raise awareness about effective opioid alternatives -- -- Multi-year initiative will leverage NFL Alumni event...